2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1245

Methotrexate Quality Improvement Project at UF Health Jacksonville Rheumatology Clinics
Abstract Number: 1246

Practices of Hydroxychloroquine Dosing Based on the American Association of Ophthalmology (AAO) 2016 Recommendations: A Single Center Experience
Abstract Number: 1247

Pharmacist-Managed Titration of Urate-Lowering Therapy to Streamline Gout Management
Abstract Number: 1248

Revisit an Old Question: Should Glucose-6-Phosphate Dehydrogenase Level be Checked in Patients with Rheumatic Diseases Prior to Initiating Certain Drugs?
Abstract Number: 1249

Contraception Compliance in Patients with Rheumatological Diseases on Disease Modifying Antirheumatic and Cytotoxic Drugs
Abstract Number: 1250

An Evaluation of Utilization Patterns and Appropriateness of Laboratory Tests Among New Referrals to Rheumatologists: Choosing Unwisely!
Abstract Number: 1251

Guideline Adherence for Perioperative Use of Immunosuppressive Medications in Patients with Rheumatologic Disease
Abstract Number: 1252

Screening for Tuberculosis before Initiating TNF Inhibitors: How Well Do We Do? a Nationwide Experience
Abstract Number: 1253

Lipid Screening and Treatment Patterns Among Patients with Rheumatic Diseases
Abstract Number: 1254

QI Project: Inpatient Practices in Ordering Fluorescent Anti-Nuclear Antibodies (F-ANA) and ANA Subserologies in a City Hospital in an Underserved Community
Abstract Number: 1255

Elevated Serum Globulin Gap As a Reliable and Cost-Savings Marker of Inflammation in Patients with Systemic Rheumatic Diseases
Abstract Number: 1256

A Customized Health Information Technology Effectively Identifies and Directs Bone Health Services in Rural Veterans with Osteoporosis Risk Factors
Abstract Number: 1257

Simple and Cost-Effective Intervention Doubled the Rate of Osteoporosis Screening in High Risk Rheumatology Patients
Abstract Number: 1258

Can Patients Enter Medical History Data By Self-Report Directly into an Electronic Medical Record (EMR)? “Private Medical History” (PMH) Software for Physician Report in EMR Format and Patient Storage to Correct and Update Medical History for Any EMR
Abstract Number: 1259

Driving Performance and Safety in Rheumatoid Arthritis: A Systematic Review

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].